Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 21, 100726
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 27 references indexed in Scilit:
- Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesMolecular Cancer, 2018
- The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature reviewOncoTargets and Therapy, 2018
- AXL and MET receptor tyrosine kinases are essential for lung cancer metastasisOncology Reports, 2017
- Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL ExpressionPLOS ONE, 2016
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene, 2015
- MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressureCurrent Opinion in Cell Biology, 2014
- Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cellsMolecular Medicine Reports, 2012
- AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian CancerCancer Research, 2010
- Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma MultiformeClinical Cancer Research, 2008
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003